Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Richardson, Debra L.
Barve, Minal A.
Strauss, James Fredric
Ulahannan, Susanna Varkey
Moore, Kathleen N.
Hamilton, Erika Paige
Johnson, Melissa Lynne
Papadopoulos, Kyriakos P.
Zarwan, Corrine
Anderson, Charles K.
Buscema, Joseph
Doroshow, Deborah Blythe
Edenfield, William Jeffery
Matulonis, Ursula A.
Burns, Timothy F.
Huebner, Dirk
Jansen, Valerie Malyvanh
Mosher, Rebecca
Jarlenski, Donna
Tolcher, Anthony W.
机构：
[1] Univ Oklahoma, Hlth Sci Ctr, Sarah Cannon Res Inst, Stephenson Canc Ctr, Oklahoma City, OK USA
[2] Mary Crowley Canc Res Ctr, Dallas, TX USA
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA
[5] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA
[6] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA
[7] South Texas Accelerated Res Therapeut LLC, San Antonio, TX USA
[8] Lahey Hosp & Med Ctr, Burlington, MA USA
[9] Willamette Valley Canc Inst, Eugene, OR USA
[10] Arizona Oncol Associates, Tucson, AZ USA
[11] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA
[12] Prisma Hlth Upstate Canc Inst, Inst Translat Oncol Res, Greenville, SC USA
[13] Dana Farber Canc Inst, Boston, MA 02115 USA
[14] Univ Pittsburgh, Med Ctr UPMC, Hillman Canc Ctr, Pittsburgh, PA USA
[15] Mersana Therapeut Inc, Cambridge, MA USA
[16] NEXT Oncol, San Antonio, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3549
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase (ph) 2 study of bortezomib ± docetaxel in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC):: Preliminary results.
    Fanucchi, MP
    Belt, RJ
    Fossella, FV
    Natale, RB
    Robert, F
    Fidias, P
    Kelly, K
    Kashala, O
    Shenkein, DP
    Schiller, JH
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 643S - 643S
  • [22] Phase 1 multicenter dose escalation and dose expansion study of antibody-drug conjugate (ADC) MYTX-011 in subjects with non-small cell lung cancer.
    Spira, Alexander I.
    Johnson, Melissa Lynne
    Blumenschein, George R.
    Burns, Timothy F.
    Thompson, Jonathan Robert
    Deshpande, Amit
    Comb, William C.
    Fiske, Brian
    Gallant, Gilles
    Heist, Rebecca Suk
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): Results from a phase II study
    Brahmer, J. R.
    Govindan, R.
    Novello, S.
    Rosell, R.
    Belani, C. P.
    Atkins, J. N.
    Gillenwater, H. H.
    Tye, L.
    Chao, R.
    Socinski, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] A phase I/II study of pembrolizumab (P) with gemcitabine (G) in patients (Pts) with previously-treated advanced non-small cell lung cancer (NSCLC): Phase I safety results
    Sanborn, Rachel E.
    Duffy, Regan M.
    Fisher, Brenda K.
    Perlewitz, Kelly Shea
    Redmond, William L.
    Koguchi, Yoshinobu
    Fox, Bernard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [25] ABBV-400, a c-Met protein-targeting antibody-drug conjugate (ADC), in patients (Pts) with advanced EGFR wildtype (WT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase I study
    De Miguel, M.
    Yamamoto, N.
    Raimbourg, J.
    Cho, B. C.
    Gottfried, M.
    Stemmer, S. M.
    Goldman, J. W.
    Blaney, M. E.
    Jennaro, T.
    Vasilopoulos, A.
    Li, R. R.
    Freise, K. J.
    Aristide, M. R. Neagu
    Morrison-Thiele, G.
    Hunter, Z. N.
    Burns, M.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2024, 35 : S805 - S806
  • [26] Phase III trial comparing antibody-drug conjugate (ADC) SAR408701 with docetaxel in patients with metastatic non-squamous non-small cell lung cancer (NSQ NSCLC) failing chemotherapy and immunotherapy.
    Johnson, Melissa Lynne
    Chadjaa, Mustapha
    Yoruk, Semra
    Besse, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Phase I/II study of docetaxel (TXT) and cisplatin(CDDP) in patients with previously untreated metastatic non-small cell lung cancer (NSCLC)
    Watanabe, K
    Hayashi, I
    Segawa, Y
    Hiraki, S
    Niitani, H
    ANNALS OF ONCOLOGY, 1998, 9 : 91 - 91
  • [28] Raltitrexed ('Tomudex') and cisplatin in metastatic non-small cell lung cancer (NSCLC): Preliminary results of a Phase I dose-escalation study
    Manegold, C
    Buchholz, E
    Kloeppel, R
    Kreisel, C
    Smith, M
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S253 - S253
  • [29] Trop-2 as a therapeutic target for the antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132) in patients (pts) with previously treated metastatic small-cell lung cancer (mSCLC).
    Starodub, Alexander
    Camidge, D. Ross
    Scheff, Ronald J.
    Thomas, Sajeve Samuel
    Guarino, Michael J.
    Masters, Gregory A.
    Kalinsky, Kevin
    Gandhi, Leena
    Bardia, Aditya
    Messersmith, Wells A.
    Ocean, Allyson J.
    Maliakal, Pius P.
    Sharkey, Robert M.
    Wilhelm, Francois
    Goldenberg, David M.
    Heist, Rebecca Suk
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] Vandetanib with pemetrexed in patients with previously treated non-small cell lung cancer (NSCLC): An open-label, multicenter phase I study
    De Boer, R.
    Vansteenkiste, J.
    Humblet, Y.
    Wolf, J.
    Nogova, L.
    Ruffert, K.
    Smith, R.
    Godwood, A.
    Milenkova, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345